Biogen (BIIB) and Eisai Announce FDA's 3-Month Extension of Review Period for BLA for Aducanumab

Go back to Biogen (BIIB) and Eisai Announce FDA's 3-Month Extension of Review Period for BLA for Aducanumab

Biogen (BIIB) Reports FDA Approval of PLEGRIDY (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis

February 1, 2021 7:33 AM EST

Biogen Inc. (NASDAQ: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has approved a new intramuscular (IM) injection route of administration for PLEGRIDY® (peginterferon beta-1a) for the treatment of relapsing forms of multiple sclerosis (MS). The new IM administration offers people living with relapsing MS the well-characterized efficacy and safety of PLEGRIDY with the potential for significantly reduced injection site reactions. This... More

Stifel Upgrades Biogen (BIIB) to Buy

January 29, 2021 8:48 AM EST

Stifel analyst Paul Matteis upgraded Biogen (NASDAQ: BIIB) from Hold to Buy with a price target of $358.00 (from $258.00).

The analyst comments "Our initial reaction after the Aducanumab AdComm was that the path to FDA approval seems challenging. Since, Biogen management's... More

Biogen (BIIB) Climbs 12% Pre-Open

January 29, 2021 7:41 AM EST

Biogen (NASDAQ: BIIB) Climbs 12% Pre-Open

Earlier Biogen (BIIB) and Eisai Announce FDA's 3-Month Extension of Review Period for BLA for Aducanumab... More